Rhythm360 / CRT-A
Atrial Fibrillation in patients with Heart Failure with Preserved Ejection Fraction (AF-HFpEF) and Post-Cardiac Surgery AF
Key Facts
About Maxwell Biomedical
Maxwell Biomedical is pioneering a paradigm shift in atrial fibrillation treatment with its Rhythm360 system and CRT-A therapy. Unlike current ablative or pharmacologic rhythm control strategies, CRT-A aims to resynchronize atrial activation to restore the heart's natural pumping mechanics without destroying tissue, targeting the unmet need of atrial dysfunction in AF-HFpEF patients. The company, led by a seasoned medtech team, is in the development stage, having recently secured a new financing round to advance its technology. Its approach represents a potential new class of therapy that could improve hemodynamics and outcomes for large patient populations currently lacking adequate device solutions.
View full company profile